



US008067202B2

(12) **United States Patent**
Ulrich et al.

(10) **Patent No.:** **US 8,067,202 B2**
(45) **Date of Patent:** **Nov. 29, 2011**

(54) **BACTERIAL SUPERANTIGEN VACCINES**

(75) Inventors: **Robert G. Ulrich**, Frederick, MD (US);
Mark A. Olson, Gaithersburg, MD (US);
Sina Bavari, Dillsburg, PA (US)

(73) Assignee: **The United States of America as represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/151,497**

(22) Filed: **May 7, 2008**

(65) **Prior Publication Data**

US 2009/0068226 A1 Mar. 12, 2009

Related U.S. Application Data

(62) Division of application No. 10/767,687, filed on Jan. 29, 2004, now Pat. No. 7,378,257, which is a division of application No. 08/882,431, filed on Jun. 25, 1997, now Pat. No. 6,713,284.

(51) **Int. Cl.**
C12N 15/09 (2006.01)

(52) **U.S. Cl.** **435/69.3**; 435/69.1; 435/71.1;
435/320.1; 435/325; 435/252.3; 435/252.33;
536/23.1; 536/23.7

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,399,332 B1 6/2002 Ulrich et al. 435/69.3
6,713,284 B2 3/2004 Ulrich et al. 435/69.3
7,087,235 B2 8/2006 Ulrich et al. 424/236.1

OTHER PUBLICATIONS

Papageorgiou et al., Journal of Molecular Biology, 260:553-569, 1996.*
Bavari et al., "Engineered Bacterial Superantigen Vaccines", Vaccines 96, pp. 135-141 (1996).

Bavari et al., "Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of *Staphylococcus enterotoxin A*", J. Infectious Diseases, 1996, 174:338-345.

Hurley et al., "Identification of Class II Major Histocompatibility Complex and T Cell Receptor Binding Sites in the Superantigen Toxic Shock Syndrome Toxin 1", J. Exp. Med., vol. 181, 2229-2235, Jun. 1995.

Stiles, et al., "Toxicity of *Staphylococcal enterotoxins* Potentiated by Lipopolysaccharide: Major Histocompatibility Complex Class II Molecule Dependency and Cytokine Release", Infection and Immunity, vol. 61, No. 12, pp. 5333-5338, Dec. 1993.

Dannecker et al. (1994) Activation of human T cells by the superantigen *Staphylococcus enterotoxin B*: Analysis on a cellular level. *Immunobiology* 190: 116-126.

Gonzalo et al. (1992) Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway. *Eur. J. Immunol.* 22: 1007-1011.

Bavari et al. (1995) Genetically attenuated bacterial superantigen vaccines. *J. Cellular Biochemistry Suppl* 21A, abstract C2-204 p. 88.

Bavari et al. (1995) *Staphylococcal enterotoxin A* and toxin shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding. *Infection and Immunity* 63:423-429.

Mahana et al. (1995) A natural mutation of the amino acid residue at position 60 destroys *Staphylococcal enterotoxin A* murine T-cell mitogenicity. *Infection and Immunity* 63:2826-2832.

Woody et al. (1998) Differential immune responses to *Staphylococcal enterotoxin B* mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors. *J. Infectious Diseases* 177: 1013-1022

Ulrich, R. G. et al. (1995) *Staphylococcal enterotoxins A* and B share a common structural motif for binding class II major histocompatibility complex molecules. *Nature Structural Biology* 2:554-560.

Ulrich, R. G. et al. (1995) Bacterial superantigens in human disease: structure, function and diversity. *Trends in Microbiology* 3: 463-468.

* cited by examiner

Primary Examiner — Marianne P Allen

(74) *Attorney, Agent, or Firm* — Elizabeth Arwine

(57) **ABSTRACT**

The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

14 Claims, 8 Drawing Sheets